Hepatitis B Surface Antigens (HBsAg)

Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.

Also Known As:

Networked: 13732 relevant articles (551 outcomes, 1459 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Kao, Jia-Horng: 60 articles (10/2021 - 10/2002)
2.	Tanaka, Yasuhito: 56 articles (09/2022 - 04/2005)
3.	Yuen, Man-Fung: 55 articles (05/2022 - 06/2004)
4.	Lu, Sheng-Nan: 53 articles (10/2022 - 01/2002)
5.	Chen, Ding-Shinn: 44 articles (01/2020 - 06/2002)
6.	Liaw, Yun-Fan: 43 articles (10/2022 - 06/2002)
7.	Chen, Pei-Jer: 43 articles (01/2022 - 07/2002)
8.	Janssen, Harry L A: 42 articles (01/2022 - 02/2006)
9.	Fung, James: 41 articles (05/2022 - 10/2006)
10.	Lai, Ching-Lung: 40 articles (01/2022 - 01/2003)

Related Diseases

1.	Infections 11/29/2021 - "Conclusions: The HISCL HBsAg assay, with a highly sensitive LoQ of 0.03 IU/mL, showed similar analytical performance in HBsAg quantification to the Elecsys HBsAg II quant assay and may be helpful in obtaining better diagnoses and therapeutic strategies for treating HBV infections." 10/01/2017 - "Most co-infected patients with HBsAg-seroconversion produced and maintained stable antibody levels, yet kinetics of anti-HBs production were much slower compared to those observed post-vaccination or after clearance of acute HBV-infection." 09/01/2015 - "Although genomic detection is considered the gold standard test on HBV infection identification, the HBsAg investigation is still the most frequent clinical laboratory request to diagnose HBV infection in activity. " 05/12/2015 - "Moreover, in most clinically studied samples, HDV infection is associated with a dramatically reduced HBV viral load, temporarily or permanently, while HBsAg resources are available for HDV packaging. " 01/01/2020 - "Further improvement in the systematic study of populations with low-level HBsAg has important clinical and epidemiological significance for improving the detection of HBV serological markers, elucidating the mechanisms leading to low-level HBsAg, overcoming immune tolerance to eliminate HBV infection and preventing HBV transmission."
2.	Hepatitis B 01/01/2022 - "HBsAg clearance represents clinical cure for patients with hepatitis B, but remains difficult to obtain for most HBV-infected patients. " 01/01/2020 - "By the end of 2018, 189 countries adopted universal hepatitis B vaccination program, which has dramatically reduced the global prevalence of HBsAg in children <5 y of age, from 4.7% in the prevaccine era to 1.3% in 2015. " 05/01/2010 - "In addition, the very large population of patients who have been exposed to the virus and have apparently cleared the virus as assessed by serological testing (HBsAg negative/hepatitis B core antibody [HBcAb] positive) may also be at risk of reactivation. " 01/01/2003 - "-B(Eng) had excellent protective efficacy against HBsAg carriage in healthy infants and children, and in neonates born to hepatitis B carrier mothers (protective efficacy of 95-99%). " 08/01/1994 - "The results show that long-term protection against HBsAg carriage of hepatitis B vaccination is very high and that a booster dose at school age does not significantly increase this protection."
3.	Chronic Hepatitis B 01/01/1999 - "Spontaneous clearance of hepatitis B surface antigen in chronic hepatitis B virus infection confers a favorable response." 08/01/2018 - "The aim of the study was to evaluate the agreement of serum HBsAg by Lumipulse HBsAg-HQ (HBsAg-HQ) with HBsAg by Architect HBsAg-QT (HBsAg-QT) and comparatively investigate the efficacy of serum HBsAg-HQ and HBsAg-QT in predicting the liver tissue pathological states of chronic hepatitis B (CHB) patients. " 04/28/2023 - "Functional cure (FC) is characterized by the clearance of the hepatitis B surface antigen from the serum of patients with chronic hepatitis B (CHB). " 10/01/2019 - "HBsAg loss is associated with functional remission and improved long-term outcome, and is considered to be a 'functional cure' (also referred to as clinical or immunologic cure) for chronic hepatitis B. " 11/01/2017 - "All chronic hepatitis B patients under medical care in Hospital Authority, Hong Kong who had cleared HBsAg between January 2000 and August 2016 were identified. "
4.	Hepatitis 07/01/1985 - "Kinetics of synthesis of anti-pre-S antibody in the course of acute type hepatitis followed by elimination of HBsAg and recovery suggest the important role of this antibody in immunological neutralization and clearance of infective HBV particles. " 01/01/2020 - "Timely re-treatment in 16 patients with increasing qHBsAg during hepatitis flare (Pattern I HBV/ALT kinetics) not only improved hepatitis and rescued impending/ensuring hepatic decompensation but also led to 'rapid HBsAg decline' with 14 patients showing HBsAg decline >1-4 log10  IU/mL within 12 months. " 01/01/2018 - "The magnitude of qHBsAg decline and rate of "rapid HBsAg decline" by month 6 was significantly greater and more frequent in group A (-0.446 vs -0.042 log10 IU/mL; 45.1 vs 8.8%, respectively, P = 0.000) than in the remaining 205 patients without on-treatment ALT elevation (group B), being greatest in patients with hepatitis flare (group A-2: -0.559 log10 IU/mL and 57.1%, respectively). " 05/01/2007 - "In multivariate analysis, the probability of HBsAg seroclearance correlated positively with age at entry (P<0.0001) and sustained remission of hepatitis (P<0.0001) and marginally significantly with male sex (P=0.053). " 03/26/1999 - "Concerning the vaccination impact on HBV endemicity in Italy, we found a significant reduction of acute viral hepatitis incidence (4.2/100,000 in 1996 versus 19/100,000 in the '80s) and HBsAg carrier prevalence (0.9% in 1997 versus 3% in the '80s). "
5.	Chronic Hepatitis (Chronic Active Hepatitis) 06/01/1981 - "These results would suggest the possibility of a spontaneous complete remission of HBsAg positive chronic active hepatitis in children but also raise doubts about the usefulness of immunosuppressive therapy in such patients." 02/01/1985 - "The efficacy of immunosuppressive treatment was evaluated in a group of 15 children (aged 2-10 years) affected by clinically asymptomatic, biochemically mild, HBSAg-positive, delta-antibody-negative, histologically moderate, chronic active hepatitis (CAH). " 04/01/1978 - "A study of lymphocyte cytotoxicity for rabbit hepatocyte cultures in 15 patients with untreated chronic active hepatitis showed positive results in all cases, both HBsAg positive and negative. " 08/01/2001 - "After 4 years of follow-up, six of the 60 patients who underwent re-evaluation (10%) had cleared the HBsAg: three of the six patients had minimal changes at the initial liver histology and normal ALT, whereas in the remaining three patients with chronic active hepatitis ALT normalized during the observation. " 01/01/1986 - "A chronic hepatitis has been also diagnosed in four out of the 15 patients who cleared their serum HBsAg. "

Related Drugs and Biologics

1.	Hepatitis B Surface Antigens (HBsAg)
2.	Hepatitis B e Antigens
3.	DNA (Deoxyribonucleic Acid)
4.	Antigens
5.	Vaccines
6.	Lamivudine (Epivir)
7.	Surface Antigens (Surface Antigen)
8.	Immunoglobulins (Immunoglobulin)
9.	hepatitis B hyperimmune globulin
10.	Antiviral Agents (Antivirals)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Liver Transplantation
4.	Aftercare (After-Treatment)
5.	Immunotherapy